ID   EPHB6_HUMAN             Reviewed;        1021 AA.
AC   O15197; A4D2I7; A8CDT5; D3DXD3; Q2TB23; Q2TB24;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 4.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=Ephrin type-B receptor 6;
DE   AltName: Full=HEP;
DE   AltName: Full=Tyrosine-protein kinase-defective receptor EPH-6;
DE   Flags: Precursor;
GN   Name=EPHB6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=9207182; DOI=10.1006/bbrc.1997.6812;
RA   Matsuoka H., Iwata N., Ito M., Shimoyama M., Nagata A., Chihara K.,
RA   Takai S., Matsui T.;
RT   "Expression of a kinase-defective Eph-like receptor in the normal
RT   human brain.";
RL   Biochem. Biophys. Res. Commun. 235:487-492(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-122; ARG-282;
RP   ALA-324 AND GLN-499.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-1021 (ISOFORM 3).
RX   PubMed=18425388;
RA   Jin M., Komohara Y., Shichijo S., Harada M., Yamanaka R., Miyamoto S.,
RA   Nikawa J., Itoh K., Yamada A.;
RT   "Identification of EphB6 variant-derived epitope peptides recognized
RT   by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.";
RL   Oncol. Rep. 19:1277-1283(2008).
RN   [8]
RP   PROTEIN SEQUENCE OF 32-46.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [9]
RP   INTERACTION WITH CBL AND EPHB1, AND PHOSPHORYLATION.
RX   PubMed=11713248; DOI=10.1074/jbc.M108011200;
RA   Freywald A., Sharfe N., Roifman C.M.;
RT   "The kinase-null EphB6 receptor undergoes transphosphorylation in a
RT   complex with EphB1.";
RL   J. Biol. Chem. 277:3823-3828(2002).
RN   [10]
RP   FUNCTION.
RX   PubMed=12517763; DOI=10.1074/jbc.M208179200;
RA   Freywald A., Sharfe N., Rashotte C., Grunberger T., Roifman C.M.;
RT   "The EphB6 receptor inhibits JNK activation in T lymphocytes and
RT   modulates T cell receptor-mediated responses.";
RL   J. Biol. Chem. 278:10150-10156(2003).
RN   [11]
RP   FUNCTION, INTERACTION WITH FYN, AND PHOSPHORYLATION.
RX   PubMed=15955811; DOI=10.1074/jbc.M500010200;
RA   Matsuoka H., Obama H., Kelly M.L., Matsui T., Nakamoto M.;
RT   "Biphasic functions of the kinase-defective Ephb6 receptor in cell
RT   adhesion and migration.";
RL   J. Biol. Chem. 280:29355-29363(2005).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=18754880; DOI=10.1111/j.1349-7006.2008.00866.x;
RA   Jin M., Komohara Y., Shichijo S., Yamanaka R., Nikawa J., Itoh K.,
RA   Yamada A.;
RT   "Erythropoietin-producing hepatocyte B6 variant-derived peptides with
RT   the ability to induce glioma-reactive cytotoxic T lymphocytes in human
RT   leukocyte antigen-A2+ glioma patients.";
RL   Cancer Sci. 99:1656-1662(2008).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=19234485; DOI=10.1038/onc.2009.18;
RA   Fox B.P., Kandpal R.P.;
RT   "EphB6 receptor significantly alters invasiveness and other phenotypic
RT   characteristics of human breast carcinoma cells.";
RL   Oncogene 28:1706-1713(2009).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-360; PRO-603; GLN-719 AND GLY-930.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-122; THR-170; VAL-221; HIS-282;
RP   GLN-309; ALA-324; LEU-332; VAL-662; SER-743; HIS-813; LYS-875 AND
RP   VAL-993.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Kinase-defective receptor for members of the ephrin-B
CC       family. Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion
CC       and migration by exerting both positive and negative effects upon
CC       stimulation with ephrin-B2. Inhibits JNK activation, T-cell
CC       receptor-induced IL-2 secretion and CD25 expression upon
CC       stimulation with ephrin-B2. {ECO:0000269|PubMed:12517763,
CC       ECO:0000269|PubMed:15955811}.
CC   -!- SUBUNIT: Interacts with CBL and EPHB1. Interacts with FYN; this
CC       interaction takes place in a ligand-independent manner.
CC       {ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:15955811}.
CC   -!- INTERACTION:
CC       Q0VD86:INCA1; NbExp=5; IntAct=EBI-10182490, EBI-6509505;
CC       Q9GZT8:NIF3L1; NbExp=3; IntAct=EBI-10182490, EBI-740897;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-10182490, EBI-945833;
CC       Q04864:REL; NbExp=3; IntAct=EBI-10182490, EBI-307352;
CC       P15884:TCF4; NbExp=3; IntAct=EBI-10182490, EBI-533224;
CC       Q9HCM9:TRIM39; NbExp=3; IntAct=EBI-10182490, EBI-739510;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O15197-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15197-2; Sequence=VSP_037496;
CC       Name=3; Synonyms=EphB6v;
CC         IsoId=O15197-3; Sequence=VSP_037497, VSP_037498;
CC   -!- TISSUE SPECIFICITY: Expressed in brain. Expressed in non invasive
CC       breast carcinoma cell lines (at protein level). Strong expression
CC       in brain and pancreas, and weak expression in other tissues, such
CC       as heart, placenta, lung, liver, skeletal muscle and kidney.
CC       Expressed in breast non invasive tumors but not in metastatic
CC       lesions. Isoform 3 is expressed in cell lines of glioblastomas,
CC       anaplastic astrocytomas, gliosarcomas and astrocytomas. Isoform 3
CC       is not detected in normal tissues. {ECO:0000269|PubMed:18754880,
CC       ECO:0000269|PubMed:19234485, ECO:0000269|PubMed:9207182}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive. Its extracellular domain is capable of promoting cell
CC       adhesion and migration in response to low concentrations of
CC       ephrin-B2, but its cytoplasmic domain is essential for cell
CC       repulsion and inhibition of migration induced by high
CC       concentrations of ephrin-B2.
CC   -!- PTM: Ligand-binding increases phosphorylation on tyrosine
CC       residues. Phosphorylation on tyrosine residues is mediated by
CC       transphosphorylation by the catalytically active EPHB1 in a
CC       ligand-independent manner. Tyrosine phosphorylation of the
CC       receptor may act as a switch on the functional transition from
CC       cell adhesion/attraction to de-adhesion/repulsion.
CC       {ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:15955811}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD03058.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAI10608.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAP20939.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA21560.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=EAL23775.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW51902.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ephb6/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHB6ID40471ch7q34.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D83492; BAA21560.1; ALT_INIT; mRNA.
DR   EMBL; AY280502; AAP20939.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF107256; AAD03058.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AC104597; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236959; EAL23775.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471198; EAW51900.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51901.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51902.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471198; EAW51903.1; -; Genomic_DNA.
DR   EMBL; BC051028; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC110606; AAI10607.1; -; mRNA.
DR   EMBL; BC110607; AAI10608.2; ALT_INIT; mRNA.
DR   EMBL; EU054308; ABV55388.1; -; mRNA.
DR   PIR; JC5526; JC5526.
DR   RefSeq; NP_001267724.2; NM_001280795.2.
DR   RefSeq; NP_004436.4; NM_004445.5.
DR   UniGene; Hs.380089; -.
DR   ProteinModelPortal; O15197; -.
DR   SMR; O15197; -.
DR   BioGrid; 108365; 11.
DR   IntAct; O15197; 20.
DR   MINT; MINT-1392963; -.
DR   STRING; 9606.ENSP00000376684; -.
DR   BindingDB; O15197; -.
DR   ChEMBL; CHEMBL5836; -.
DR   GuidetoPHARMACOLOGY; 1834; -.
DR   iPTMnet; O15197; -.
DR   PhosphoSitePlus; O15197; -.
DR   PaxDb; O15197; -.
DR   PeptideAtlas; O15197; -.
DR   PRIDE; O15197; -.
DR   Ensembl; ENST00000392957; ENSP00000376684; ENSG00000106123.
DR   Ensembl; ENST00000442129; ENSP00000410789; ENSG00000106123.
DR   GeneID; 2051; -.
DR   KEGG; hsa:2051; -.
DR   CTD; 2051; -.
DR   DisGeNET; 2051; -.
DR   GeneCards; EPHB6; -.
DR   HGNC; HGNC:3396; EPHB6.
DR   HPA; HPA035784; -.
DR   MIM; 602757; gene.
DR   neXtProt; NX_O15197; -.
DR   PharmGKB; PA27828; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; O15197; -.
DR   KO; K05114; -.
DR   PhylomeDB; O15197; -.
DR   TreeFam; TF314013; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   ChiTaRS; EPHB6; human.
DR   GeneWiki; EPHB6; -.
DR   GenomeRNAi; 2051; -.
DR   PRO; PR:O15197; -.
DR   Proteomes; UP000005640; Unplaced.
DR   Bgee; ENSG00000106123; -.
DR   CleanEx; HS_EPHB6; -.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; TAS:ProtInc.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Glycoprotein; Membrane; Nucleotide-binding;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     31       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        32   1021       Ephrin type-B receptor 6.
FT                                /FTId=PRO_0000016837.
FT   TOPO_DOM     32    594       Extracellular. {ECO:0000255}.
FT   TRANSMEM    595    615       Helical. {ECO:0000255}.
FT   TOPO_DOM    616   1021       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       33    237       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      369    486       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      487    582       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      670    919       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      948   1012       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     676    684       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF      1019   1021       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    166    176       Poly-Ser.
FT   COMPBIAS    219    366       Cys-rich.
FT   COMPBIAS    881    884       Poly-Pro.
FT   CARBOHYD    480    480       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ      16    292       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037496.
FT   VAR_SEQ     487    540       VPSAVPVVHQVSRASNSITVSWPQPDQTNGNILDYQLRYYD
FT                                QAEDESHSFTLTS -> GELFSLAFRIPCLRSFEPPSLLLI
FT                                SSLVHPCRPPLKADPAPRDSYPHNNFPFAL (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:18425388}.
FT                                /FTId=VSP_037497.
FT   VAR_SEQ     541   1021       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18425388}.
FT                                /FTId=VSP_037498.
FT   VARIANT     122    122       G -> S (in dbSNP:rs8177173).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019139.
FT   VARIANT     170    170       S -> T. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042190.
FT   VARIANT     221    221       A -> V. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042191.
FT   VARIANT     282    282       P -> H. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042192.
FT   VARIANT     282    282       P -> R (in dbSNP:rs8177143).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019140.
FT   VARIANT     309    309       R -> Q (in dbSNP:rs55728646).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042193.
FT   VARIANT     324    324       S -> A (in dbSNP:rs8177146).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019141.
FT   VARIANT     332    332       S -> L (in dbSNP:rs35189999).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042194.
FT   VARIANT     360    360       D -> N (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036091.
FT   VARIANT     499    499       R -> Q (in dbSNP:rs8177175).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019142.
FT   VARIANT     603    603       A -> P (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036092.
FT   VARIANT     662    662       A -> V (in dbSNP:rs35984674).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042195.
FT   VARIANT     719    719       R -> Q (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036093.
FT   VARIANT     743    743       P -> S (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042196.
FT   VARIANT     813    813       R -> H. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042197.
FT   VARIANT     875    875       E -> K (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042198.
FT   VARIANT     930    930       D -> G (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036094.
FT   VARIANT     993    993       I -> V. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042199.
SQ   SEQUENCE   1021 AA;  110700 MW;  BF1D4D9BE34358A5 CRC64;
     MATEGAAQLG NRVAGMVCSL WVLLLVSSVL ALEEVLLDTT GETSEIGWLT YPPGGWDEVS
     VLDDQRRLTR TFEACHVAGA PPGTGQDNWL QTHFVERRGA QRAHIRLHFS VRACSSLGVS
     GGTCRETFTL YYRQAEEPDS PDSVSSWHLK RWTKVDTIAA DESFPSSSSS SSSSSSAAWA
     VGPHGAGQRA GLQLNVKERS FGPLTQRGFY VAFQDTGACL ALVAVRLFSY TCPAVLRSFA
     SFPETQASGA GGASLVAAVG TCVAHAEPEE DGVGGQAGGS PPRLHCNGEG KWMVAVGGCR
     CQPGYQPARG DKACQACPRG LYKSSAGNAP CSPCPARSHA PNPAAPVCPC LEGFYRASSD
     PPEAPCTGPP SAPQELWFEV QGSALMLHWR LPRELGGRGD LLFNVVCKEC EGRQEPASGG
     GGTCHRCRDE VHFDPRQRGL TESRVLVGGL RAHVPYILEV QAVNGVSELS PDPPQAAAIN
     VSTSHEVPSA VPVVHQVSRA SNSITVSWPQ PDQTNGNILD YQLRYYDQAE DESHSFTLTS
     ETNTATVTQL SPGHIYGFQV RARTAAGHGP YGGKVYFQTL PQGELSSQLP ERLSLVIGSI
     LGALAFLLLA AITVLAVVFQ RKRRGTGYTE QLQQYSSPGL GVKYYIDPST YEDPCQAIRE
     LAREVDPAYI KIEEVIGTGS FGEVRQGRLQ PRGRREQTVA IQALWAGGAE SLQMTFLGRA
     AVLGQFQHPN ILRLEGVVTK SRPLMVLTEF MELGPLDSFL RQREGQFSSL QLVAMQRGVA
     AAMQYLSSFA FVHRSLSAHS VLVNSHLVCK VARLGHSPQG PSCLLRWAAP EVIAHGKHTT
     SSDVWSFGIL MWEVMSYGER PYWDMSEQEV LNAIEQEFRL PPPPGCPPGL HLLMLDTWQK
     DRARRPHFDQ LVAAFDKMIR KPDTLQAGGD PGERPSQALL TPVALDFPCL DSPQAWLSAI
     GLECYQDNFS KFGLCTFSDV AQLSLEDLPA LGITLAGHQK KLLHHIQLLQ QHLRQQGSVE
     V
//
